Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study

Study acronym: FLiPP
StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jun 30, 2026 → Jul 14, 2027
See other at-risk trials from University of California, Davis

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 30, 2026 to Jul 14, 2027
    • Eligibility criteria expanded, about 10 words
    • Publications: details revised at 1 of 1 entry
  2. Primary and study completion dates: Jun 30, 2025 to Jun 30, 2026v15
  3. Primary and study completion dates: Jun 30, 2024 to Jun 30, 2025v14
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v13
  5. Interventions: Fluorodeoxyglucose (FDG) positron emission tomography (PET) (Radiation), Liver magnetic resonance (MR) Perfusion (Other), Magnetic… to Fluorodeoxyglucose (FDG) positron emission tomography (PET) (Radiation), Magnetic resonance imaging (MRI) (Other), PET Explorer (Radiation)
    • Site contact updated
    • Study title revised
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Re-verified, no change to tracked fieldsv11
  2. Primary completion date: Sep 30, 2021 to Jun 30, 2024v10 Show 5 more changesShow less
    • Study completion date: Jun 30, 2022 to Jun 30, 2024
    • Interventions: FDG-PET (Radiation), Liver MR Perfusion (Other), MRI-PDFF (Other) to Fluorodeoxyglucose (FDG) positron emission tomography (PET) (Radiation), Liver magnetic resonance (MR) Perfusion (Other), Magnetic…
    • Site contact updated
    • Collaborator revised
    • Study description expanded, about 4 words
  3. Enrollment target: 50 to 120v9 Show 7 more changesShow less
    • Primary completion date: Mar 30, 2020 to Sep 30, 2021
    • Trial status: Completed to Recruiting
    • Study completion date: Mar 30, 2020 to Jun 30, 2022
    • Start date: Apr 2016 to Apr 30, 2016
    • Interventions: FDG-PET (Radiation), MRI-PDFF (Radiation) to FDG-PET (Radiation), Liver MR Perfusion (Other), MRI-PDFF (Other)
    • Site details revised
    • Collaborators expanded, about 5 words
  4. Trial status: Recruiting to Completed
    • Enrollment target: estimated 25 to confirmed 50
    • Primary and study completion dates changed from estimate of Dec 10, 2027 to Mar 30, 2020
    • Site details revised
    v8
  5. Re-verified, no change to tracked fieldsv7
  6. Primary and study completion dates: Jan 2018 to Dec 10, 2027v6
  7. Primary and study completion dates: Jul 2017 to Jan 2018v5
  8. Re-verified, no change to tracked fieldsv4
  9. Primary completion date: Jul 2016 to Jul 2017
    • Primary endpoint revised
    • Site contact updated
    v3
  10. Study description expanded, about 2 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blood test results, and imaging measurements to determine the severity of NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), inflammation, and fibrosis.
Trial Details
NCT Number NCT02754037
Lead Sponsor University of California, Davis
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Related terms Non-alcoholic Fatty Liver Disease
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov